Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

BACKGROUND: Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER(+)) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing the need for steroid hormones. Previously, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribas, Ricardo, Pancholi, Sunil, Rani, Aradhana, Schuster, Eugene, Guest, Stephanie K., Nikitorowicz-Buniak, Joanna, Simigdala, Nikiana, Thornhill, Allan, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dowsett, Mitch, Johnston, Stephen R., Martin, Lesley-Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992820/
https://www.ncbi.nlm.nih.gov/pubmed/29880014
http://dx.doi.org/10.1186/s13058-018-0983-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992820/
https://www.ncbi.nlm.nih.gov/pubmed/29880014
http://dx.doi.org/10.1186/s13058-018-0983-1

Ejemplares similares